Document ID: EPA-HQ-OPP-2023-0474-0016
Agency: epa
Document Type: Notice
Title: Endocrine Disruptor Screening Program: Near-Term Strategies for Implementation; Correction
Posted Date: 2023-12-26T05:00Z

[Federal Register Volume 88, Number 246 (Tuesday, December 26, 2023)]
[Notices]
[Pages 88907-88908]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-28510]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2023-0474; FRL-11384-03-OCSPP]

Endocrine Disruptor Screening Program (EDSP); Near-Term 
Strategies for Implementation; Notice of Availability and Request for 
Comment; Extension of Comment Period; Correction

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: In the Federal Register of December 14, 2023, EPA announced 
the extension of the comment period established in a document that 
published in the Federal Register of October 27, 2023 that announced 
the availability of and solicited comment on near-term strategies to 
help the Agency meet its obligations and commitments under the Federal 
Food, Drug, and Cosmetic Act (FFDCA), which requires, that EPA screen 
for and protect against endocrine disrupting effects in humans. This 
document corrects the extended comment period date that published in 
the Federal Register of December 14,

[[Page 88908]]

2023, which inadvertently included the incorrect year.

DATES: December 26, 2023.

ADDRESSES: Submit your comments, identified by docket identification 
(ID) number EPA-HQ-OPP-2023-0474, through the Federal eRulemaking 
Portal at https://www.regulations.gov. Follow the online instructions 
for submitting comments. Do not submit electronically any information 
you consider to be Confidential Business Information (CBI) or other 
information whose disclosure is restricted by statute. Additional 
instructions on commenting and visiting the docket, along with more 
information about dockets generally, is available at https://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Catherine Aubee, Endocrine Disruptor 
Screening Program (7505T), Office of Pesticide Programs, Environmental 
Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-
0001; main telephone number: (202) 566-1030; email address: 
[email protected].

SUPPLEMENTARY INFORMATION: To give stakeholders additional time to 
review materials and prepare comments, EPA extended the comment period 
established in the Federal Register document of October 27, 2023, at 88 
FR 73841 (FRL-11384-01-OCSPP) for 60 days, from December 26, 2023. 
However, the extended comment period date established in the Federal 
Register document of December 14, 2023, at 88 FR 86644 (FRL-11384-02-
OCSPP), was incorrectly stated as February 26, 2023. This notice 
corrects the comment period date to February 26, 2024. More information 
on the action can be found in the Federal Register of October 27, 2023.

Correction

    In the Federal Register of December 14, 2023, in FR Doc. 2023-
27405, on page 86644, in the first column, correct the Dates caption to 
read:

DATES: The comment period for the document published in the Federal 
Register of October 27, 2023, at 88 FR 73841 (FRL-11384-01-OCSPP) is 
extended. Comments must be received on or before February 26, 2024.

    Authority: 7 U.S.C. 136 et seq. and 21 U.S.C. 346a.

    Dated: December 20, 2023.
Angela Hofmann,
Director, Regulatory Support Branch, Mission Support Division, Office 
of Program Support, Office of Chemical Safety and Pollution Prevention.
[FR Doc. 2023-28510 Filed 12-22-23; 8:45 am]
BILLING CODE 6560-50-P